---
layout: default
title: Ropivacaine
parent: 僅模型預測 (L5)
nav_order: 178
evidence_level: L5
indication_count: 10
---

# Ropivacaine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ropivacaine: From Regional Anaesthesia to Migraine Disorder

## One-Sentence Summary

Ropivacaine is a long-acting amide local anaesthetic used in clinical practice for regional anaesthesia and interventional pain management procedures.
The TxGNN model predicts it may be effective for **Migraine Disorder**, with **4 clinical trials** and **6 publications** currently supporting this direction.
Evidence is at Level L2, anchored by a completed Phase 4 double-blind RCT and a paediatric emergency department trial involving 150 participants.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Regional anaesthesia and pain management (no MHRA marketing authorisation on record) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L2 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Why is This Prediction Reasonable?

Ropivacaine is a long-acting amide local anaesthetic whose principal mechanism is voltage-gated sodium channel (Nav channel) blockade, inhibiting the initiation and propagation of nerve action potentials. Although detailed mechanism of action data was not available in the current Evidence Pack, Nav-channel blockade is Ropivacaine's well-established pharmacological basis and underpins every plausible route through which it could influence migraine.

The application to migraine is mechanistically coherent. Migraine pathophysiology involves activation of the trigeminovascular system, peripheral sensitisation of nociceptors around meningeal blood vessels, and amplification of pain signals through autonomic relay stations — most notably the sphenopalatine ganglion (SPG). Ropivacaine delivered via SPG block, trigger point injection, or stellate ganglion block can interrupt these pain transmission circuits directly. The SPG in particular plays a pivotal role in propagating both the pain and the autonomic features (lacrimation, nasal congestion) characteristic of migraine attacks, making it a recognised interventional target.

Early clinical data are encouraging. A completed Phase 4 double-blind RCT (NCT03666663) directly evaluated SPG blocks with local anaesthetics for migraine prevention, and a completed unphased trial (NCT00680823, n=150) studied intramuscular Ropivacaine for paediatric headache in an emergency department setting. Multiple observational studies provide further biological plausibility, with one 2007 prospective cohort study specifically evaluating Ropivacaine trigger point injections for prophylactic migraine management over 12 weeks. The convergence of mechanism, interventional precedent, and early-phase data makes the TxGNN prediction scientifically credible.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrolment | Key Findings |
|---------|------|------|------|---------|
| [NCT00680823](https://clinicaltrials.gov/study/NCT00680823) | N/A | Completed | 150 | Largest completed trial for this drug–indication pair: evaluated lower paracervical intramuscular Ropivacaine injection as a treatment for headache in a paediatric emergency department |
| [NCT03666663](https://clinicaltrials.gov/study/NCT03666663) | Phase 4 | Completed | 10 | Double-blind RCT of SPG block using local anaesthetics vs placebo for migraine prevention in adults; directly relevant but substantially limited by very small sample size |
| [NCT05301387](https://clinicaltrials.gov/study/NCT05301387) | N/A | Completed | 38 | Assessed long-term effects of SPG block on post-dural puncture headache; mechanistically related (SPG pathway) but target population is PDPH rather than primary migraine |
| [NCT06470581](https://clinicaltrials.gov/study/NCT06470581) | N/A | Not yet recruiting | 78 | Prospective RCT comparing botulinum toxin A vs local anaesthetic for thoracic sympathetic ganglion block in upper-limb CRPS; Ropivacaine likely serves as comparator only — not yet commenced |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|---------|
| [35331152](https://pubmed.ncbi.nlm.nih.gov/35331152/) | 2022 | Observational Study | BMC Anesthesiology | Ultrasound-guided stellate ganglion block observed to effectively relieve migraine pain and improve quality of life; supports ganglion-blockade approach in migraine |
| [30043973](https://pubmed.ncbi.nlm.nih.gov/30043973/) | 2019 | Observational Study | Headache | Regional anaesthetic SPG block reduced self-reported pain in status migrainosus (migraine >72 hours); reinforces SPG as a strategic therapeutic target |
| [17244105](https://pubmed.ncbi.nlm.nih.gov/17244105/) | 2007 | Prospective Cohort | Pain Medicine | Ropivacaine trigger point injections over 12 weeks evaluated for prophylactic management of severe migraine; sole study directly assessing Ropivacaine for migraine prevention |
| [24284858](https://pubmed.ncbi.nlm.nih.gov/24284858/) | 2013 | Case Series / Technique Report | Pain Physician | Described a revised transnasal topical SPG block technique for headache and facial pain; supports SPG as accessible interventional target with favourable risk profile |
| [17058040](https://pubmed.ncbi.nlm.nih.gov/17058040/) | 2006 | Case Report | J Headache Pain | Migraine headache reported as rare complication after cervicothoracic block; provides indirect mechanistic insight into local anaesthetic–trigeminal pain circuit interactions |
| [19145569](https://pubmed.ncbi.nlm.nih.gov/19145569/) | 2009 | Case Report | Revista de Neurologia | Horner's syndrome following epidural analgesia; limited direct relevance to migraine treatment — included for completeness |

---

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails**

**Rationale:**
A completed Phase 4 RCT and the largest available paediatric headache trial (n=150) — together with a coherent Nav-channel / trigeminovascular mechanistic rationale and multiple supporting observational studies — provide an L2 evidence base sufficient to justify further development, provided appropriate safeguards are in place to address current data gaps.

**To proceed, the following is needed:**

- **Mechanism of action data**: Retrieve full pharmacological profile from DrugBank to formalise the Nav-channel / trigeminovascular mechanistic narrative
- **Safety review**: Obtain full SmPC (MHRA/EMA) to complete warnings, contraindications, and drug interaction profiling prior to any clinical development
- **Larger confirmatory RCT**: A well-powered trial (target n ≥ 100) in adult primary migraine using SPG block with Ropivacaine; the existing Phase 4 trial (n=10) is underpowered to support regulatory claims
- **Dose and route standardisation**: Define the optimal administration route (transnasal, infrazygomatic, or catheter-based SPG block) and dose range for the migraine indication
- **UK regulatory pathway**: Consult MHRA regarding the route to a new indication given Ropivacaine currently holds no UK marketing authorisation; a Marketing Authorisation Application (MAA) or an off-label use framework would need to be identified
- **Paediatric data review**: The NCT00680823 paediatric dataset (n=150) should be formally analysed and published to strengthen the evidence base
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

